Compare Nutrien Ltd (NTR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Travere Therapeutics Inc. Common Stock — how do they compare? Nutrien Ltd trades at $69.87 (market cap $33.13B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Nutrien Ltd is far larger — about 6.8× Travere Therapeutics Inc. Common Stock's market cap, and Nutrien Ltd pays a 3.16% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 60 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NTR | TVTX | |
|---|---|---|
Market Cap | $33.13B | $4.88B |
Volume | 2,165,412 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $67.52 |
52-Week Low | $53.64 | $26.79 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $44.94B | $5.01B |
Dividend Yield | 3.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTR trades at $69.87, up 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. The company demonstrates solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation ratios including P/E of 14.11. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations. Analyst sentiment remains positive with 60.61% buy ratings and $77.29 consensus target.
NTR presents a compelling value opportunity with reasonable valuations and strong cash flow generation, though facing headwinds from fertilizer industry challenges and competitive pressures. The stock's current discount to analyst targets suggests potential upside, but investors should monitor execution on cost discipline and volume recovery amid fluctuating commodity prices and geopolitical factors affecting fertilizer markets.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
